Membranous glomerulonephritis primary prevention

Jump to navigation Jump to search

Membranous glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranous glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

Ultrasound

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranous glomerulonephritis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranous glomerulonephritis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranous glomerulonephritis primary prevention

CDC on Membranous glomerulonephritis primary prevention

Membranous glomerulonephritis primary prevention in the news

Blogs on Membranous glomerulonephritis primary prevention

Directions to Hospitals Treating Membranous glomerulonephritis

Risk calculators and risk factors for Membranous glomerulonephritis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Ahsan Hussain, M.D.[2]

Overview

Vaccine against heptatis B and treatment of hepatitis C can be preventive for membranous glomerulopathy.

Primary Prevention

  • Effective measures for primary prevention of membranous glomerulonephritis include:[1][2]
    • Vaccine against hepatitis B can prevent hepatitis B which can lower the risk for membranous glomerulonephritis.
    • The treatment of hepatitis C can prevent the can lower the risk for membranous glomerulonephritis.

References

  1. Lai, Kar Neng; Li, Philip K.T.; Lui, Siu Fai; Au, Tak Cheong; Tam, John S.L.; Tong, Kwok Lung; Lai, Fernand Mac-Moune (1991). "Membranous Nephropathy Related to Hepatitis B Virus in Adults". New England Journal of Medicine. 324 (21): 1457–1463. doi:10.1056/NEJM199105233242103. ISSN 0028-4793.
  2. Gyapay G, Jeney A, Lapis K (1985). "Drug action and chromatin structure. I. Adriamycin binding to core particle of nucleosomes and subsequent enhanced DNA fragmentation induced by micrococcal nuclease". Neoplasma. 32 (5): 521–8. PMID 4069286.

Template:WH Template:WS